Korean Circ J.
1976 Dec;6(2):17-23. 10.4070/kcj.1976.6.2.17.
Clinical Evaluation of Tibric Acid in Patients with Hyperlipidemia
- KMID: 1667923
- DOI: http://doi.org/10.4070/kcj.1976.6.2.17
Abstract
- Tibric acid is a new oral hypolipidemic agent with the chemical name of 2-chloro-5(3,5-dimethyl piperidinosulfonyl) benzoic acid. The results of tibric acid administration in 22 patients with primary hyperlipidemia were as follows. 1) Serum triglyceride level was significantly decreased in 84.6% of 22 cases with an average 43.9% decrease in serum triglyceride. 2) Serum cholesterol level was decreased in 59.1% of 22 cases with an average 15.8% decrease in serum cholesterol. The decrease in serum cholesterol level was not significant. 3) It seemed that there were significant falls in the serum triglyceride of the hyperlipoproteinemia type IV and IIb patietns and in the serum cholesterol of type IIa patients 4) The side effects of tibric acid were indigestion, loose stool and anorexia. There was no side effects in 63.6% of cases.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy of Ciprofibrate Monotherapy in Patients with Type II and Type IV Hyperlipidemia
- A Case of Acute Pancreatitis in a Neuroblastoma Patient after Retinoic Acid Therapy
- Systematic Evaluation and Meta-Analysis of the Effect of Gynostemma pentaphyllum on Clinical Indexes of Hyperlipidemia
- Xanthoma of the liver in a patient with multiple myeloma associated with hyperlipidemia: A case report
- Lipid Profile in Patients with Osteonecrosis of the Femoral Head
